☆ 4.6 Article

High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19 a randomised, placebo-controlled trial

LANCET RESPIRATORY MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

(A Little) Clarity on Convalescent Plasma for Covid-19

Louis M. Katz

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Medicine, General & Internal

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

Perrine Janiaud et al.

Summary: Convalescent plasma treatment showed no significant decrease in all-cause mortality or benefit for other clinical outcomes compared to placebo or standard of care. The certainty of the evidence ranged from low to moderate for all-cause mortality and remained low for other outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Benjamin Trinite et al.

Summary: The levels of neutralizing antibodies significantly increase with disease severity in COVID-19 patients. Hospitalized individuals have higher titers compared to those with mild symptoms or asymptomatic, with no significant impact from age, gender, or treatment on the neutralizing titers.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Medicine, General & Internal

Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial

Maria Elvira Balcells et al.

Summary: The study did not find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.

PLOS MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Peter W. Horby et al.

Summary: Convalescent plasma therapy did not improve survival or other clinical outcomes in hospitalized COVID-19 patients.

LANCET (2021)

添加到收藏夹

Article Hematology

Effect of Methylene Blue Pathogen Inactivation on the Integrity of Immunoglobulin M and G

Johannes Raster et al.

Summary: The study found that the use of methylene blue treatment of plasma does not inhibit the binding capacity of IgM and IgG to their epitopes, or the Fc receptor interaction of IgG.

TRANSFUSION MEDICINE AND HEMOTHERAPY (2021)

添加到收藏夹

Article Hematology

Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma

Alexander I. Kostin et al.

Summary: The study found that pathogen reduction with methylene blue or with amotosalen is more likely to preserve the immunological properties of COVID-19 convalescent plasma compared to riboflavin, which resulted in a significant decrease in quantity and activity of specific antibodies.

VOX SANGUINIS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Manaf AlQahtani et al.

Summary: The pilot study suggests that CP therapy is safe in hospitalized COVID-19 patients, but there were no significant differences in primary and secondary outcome measures compared to standard therapy. A larger definitive study is needed for confirmation.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

Philippe Begin et al.

Summary: Convalescent plasma did not reduce the risk of intubation or death at 30 days in hospitalized patients with COVID-19. Transfusion of convalescent plasma with unfavorable antibody profiles could be associated with worse clinical outcomes compared to standard care.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Convalescent Plasma for High-Risk Outpatients with Covid-19

Frederick K. Korley et al.

Summary: This study showed that administering Covid-19 convalescent plasma to high-risk outpatients within 1 week after symptom onset did not prevent disease progression.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Virology

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

Benjamin Trinite et al.

Summary: The study found that the time from natural infection and the nature of the infecting variant determined cross-neutralization; Uninfected vaccinees showed a small reduction in neutralization against the B.1.1.7 variant; Previously infected individuals developed more robust neutralizing responses against B.1.1.7 after vaccination, indicating that vaccines can enhance the neutralization breadth conferred by natural infection.

VIRUSES-BASEL (2021)

添加到收藏夹

Review Virology

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors

Daniele Focosi et al.

Summary: In addition to specific antibodies, CCP may contain other factors that could have beneficial or detrimental effects on the treatment outcomes of COVID-19 patients, which warrants further investigation.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

Arvind Gharbharan et al.

Summary: A clinical trial on 86 COVID-19 patients treated with convalescent plasma showed no overall clinical benefit, as most patients already had potent antibodies upon admission, leading to the trial being terminated prematurely.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Katie L. Kunze et al.

Summary: Successful COVID-19 therapeutics and vaccines have utilized the immune response to the virus, but locally-evolving variants may impact treatment effectiveness. Near-sourced convalescent plasma has higher efficacy in causing death within 30 days of transfusion.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, Research & Experimental

A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia

Cristina Avendano-Sola et al.

Summary: The study conducted in Spain involving 27 hospitals showed that convalescent plasma (CP) can significantly reduce the risk of progression to invasive mechanical ventilation or ECMO treatment, or death within 28 days for COVID-19 patients. However, the difference was not significant at 14 days and there was no significant improvement in overall survival.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Review Medicine, Research & Experimental

The role of biomarkers in diagnosis of COVID-19-A systematic review

Muhammed Kermali et al.

LIFE SCIENCES (2020)

添加到收藏夹

Review Immunology

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

John Mair-Jenkins et al.

JOURNAL OF INFECTIOUS DISEASES (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.